

---

National Institute for Health and Clinical Excellence

**Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2**

---

Royal College of Nursing

---

### **Introduction**

The Royal College of Nursing (RCN) was invited to review the Appraisal Consultation Document (ACD) for Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that over-expresses HER2.

Nurses caring for people with breast cancer were invited to review this document on behalf of the RCN.

### **Appraisal Consultation Document – RCN Response**

The Royal College of Nursing welcomes the opportunity to review this document. The RCN's response to the four questions on which comments were requested is set out below:

i) **Has the relevant evidence has been taken into account?**

The evidence considered seems comprehensive.

ii) **Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?**

We would ask that the summaries of the clinical and cost effectiveness of this appraisal should be aligned to the clinical pathway followed by patients with metastatic hormone-receptor-positive breast cancer that

over-expresses HER2. The preliminary views on resource impact and implications should be in line with established standard clinical practice.

iii) **Are the provisional recommendations sound and a suitable basis for guidance to the NHS?**

Nurses working in this area have reviewed the recommendations of the Appraisal Committee and do not have any other comments to make.

The RCN would welcome guidance to the NHS on the use of this health technology.

iv) **Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief?**

None that we are aware of at this stage.

v) **Are there any equality-related issues that need special consideration that are not covered in the appraisal consultation document?**

We are not aware of any specific issue at this stage. We would however, ask that any guidance issued should show that an analysis of equality impact has been considered and that the guidance demonstrates an understanding of issues relating to all the protected characteristics where appropriate.